Open Requests for Proposals (RFPs)
TB Alliance Background
TB Alliance is a product development partnership (PDP), working to discover and develop better, faster acting, and affordable drugs to fight tuberculosis. We envision a world where no one dies of tuberculosis. However, this cannot be achieved without new, better, and faster-acting tuberculosis drug regimens. The Global Alliance for TB Drug Development (TB Alliance) was established in 2000 as a not-for-profit product development partnership to lead the search for new TB regimens and catalyze global efforts for new TB regimens that can bring hope, and health, to millions.
Requests for Proposal:
Assessing Patient Experiences with Shorter All-Oral DR-TB Regimens Across Countries
TB Alliance is undertaking a multi-country, cross-sectional, mixed-methods study across eight partner countries: Brazil, Peru, Indonesia, India, Pakistan, Bangladesh, Philippines, Nigeria. Note, TB Alliance has partnered with these countries for the Fast Track the Cure (FTTC) initiative and these partners have been identified for gathering the required country data. The study will systematically document patient-reported experiences with newer DR-TB treatment regimens and generate robust, comparable evidence across regimens and settings.
The objective of this study is to (a) evaluate patients’ experiences with newer all-oral DR-TB treatment regimens in routine programmatic settings across different countries, (b) identify factors influencing treatment adherence, tolerability, psychosocial well-being, and financial burden during treatment, (c) identify key barriers and enabling factors affecting treatment adherence, tolerability, psychosocial well-being, and financial burden during treatment and (d) develop a standardized analytical framework to synthesize and compare patient-reported experiences across treatment regimens and country contexts ensuring reproducibility and long-term usability of the tool.
The findings are expected to support national TB programmes and partners in strengthening patient-centered service delivery models, improving treatment support mechanisms, and informing the effective implementation and scale-up of DR-TB treatment regimens.
- See the full RFP here.